14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
KIDS vs INMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, InMode Ltd. (INMD) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas INMD carries 38.9/100 (SELL) at $12.70 (9.3x Forward P/E, 17.9% operating margin).
Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. INMD 38.9/100 SELL), INMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (17.9% vs. -8.2% operating margin) and revenue trajectory (-1.1% vs. +18.6% YoY).
Technical & Structure Timing Caution: KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2); meanwhile INMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KIDS vs INMD. Trailing 12-month operating profitability (KIDS -8.2% vs INMD 17.9%) and valuation multiples (KIDS N/M vs INMD 9.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $741.2M market capitalization and 17.9% operating margin.
OpEx & R&D Reinvestment58.7% of Rev ($219M)
90D Engineering Disclosures0 Published
Investor FAQ KIDS vs INMD Key Questions & Quantitative Answers
As of Nov 19, 2026, InMode Ltd. (INMD) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas INMD carries 38.9/100 (SELL) at $12.70 (9.3x Forward P/E, 17.9% operating margin). Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. INMD 38.9/100 SELL), INMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (17.9% vs. -8.2% operating margin) and revenue trajectory (-1.1% vs. +18.6% YoY). Technical & Structure Timing Caution: KIDS trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 64.2); meanwhile INMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KIDS leads the Growth & Scale pillar: KIDS posts +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin), compared with INMD at -1.1% YoY revenue growth and -5.9% YoY earnings growth on $374M TTM revenue (76.6% gross margin, 17.9% operating margin). On trailing 12-month operating scale, KIDS generates $264M in USD-normalized revenue versus $374M for INMD. In operating R&D and SG&A reinvestment, KIDS deploys 82.0% of Rev ($217M) (0 90-day corporate R&D disclosures) versus 58.7% of Rev ($219M) (0 disclosures) for INMD.
INMD screens cheaper on headline valuation multiples. KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin), whereas INMD trades at 9.3x Forward P/E, 10.8x Trailing P/E, 2.90x PEG, and 0.9x EV/Revenue (18.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KIDS (-9.8% ROE) versus INMD (11.4% ROE) capital efficiency.
In options market volatility and institutional positioning, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk). By comparison, INMD carries 42.4% implied volatility (14th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.60β · 35% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.